Glucose hypometabolism is the earliest symptom observed in the brains of Alzheimer
disease (AD) patients. In a former study, we analyzed the cortical proteome of the APP23 …

Introduction The mechanistic role of amyloid precursor protein (APP) in Alzheimer's disease
(AD) remains unclear. Objectives Here, we aimed to identify alterations in cerebral …

Recent studies suggest that the neurobiology of Alzheimer's disease (AD) pathology could
not be explained solely by an increase in β-amyloid levels. In fact, success with potential …

Alzheimer's disease (AD) is regarded as a metabolic disorder, and more attention has been
paid to brain metabolism. However, AD may also affect metabolism in the peripheral organs …

The present study had focused on the behavioral phenotype and gene expression profile of
molecules related to insulin receptor signaling in the hippocampus of 3 and 6 month-old …

Alzheimer's disease (AD) is an amyloid-related neurodegenerative disorder and is also
considered to be a metabolic disease. Thus, investigation of metabolic mechanisms of …

Alzheimer disease (AD) is a progressive neurodegenerative disease that affects the elderly
population with complex etiology. Many hypotheses have been proposed to explain different …

Alzheimer disease (AD) is the most common type of dementia and is characterized
pathologically by the presence of neurofibrillary tangles (NFTs), senile plaques (SPs), and …

A central issue in the field of Alzheimer's disease (AD) is to separate the cause from the
consequence among many observed pathological features, which may be resolved by …

Accumulation of amyloid β-peptide (Aβ) is a driver of Alzheimer's disease (AD). Amyloid
precursor protein (App) knock-in mouse models recapitulate AD-associated Aβ pathology …